Loss of the Chr16p11.2 ASD candidate gene QPRT leads to aberrant neuronal differentiation in the SH-SY5Y neuronal cell model by Haslinger, Denise et al.
RESEARCH Open Access
Loss of the Chr16p11.2 ASD candidate
gene QPRT leads to aberrant neuronal
differentiation in the SH-SY5Y neuronal cell
model
Denise Haslinger1, Regina Waltes1, Afsheen Yousaf1, Silvia Lindlar1, Ines Schneider2, Chai K. Lim3, Meng-Miao Tsai4,
Boyan K. Garvalov4,5, Amparo Acker-Palmer6, Nicolas Krezdorn7, Björn Rotter7, Till Acker4, Gilles J. Guillemin3,
Simone Fulda2, Christine M. Freitag1 and Andreas G. Chiocchetti1*
Abstract
Background: Altered neuronal development is discussed as the underlying pathogenic mechanism of autism spectrum
disorders (ASD). Copy number variations of 16p11.2 have recurrently been identified in individuals with ASD. Of the 29
genes within this region, quinolinate phosphoribosyltransferase (QPRT) showed the strongest regulation during neuronal
differentiation of SH-SY5Y neuroblastoma cells. We hypothesized a causal relation between this tryptophan metabolism-
related enzyme and neuronal differentiation. We thus analyzed the effect of QPRT on the differentiation of SH-SY5Y and
specifically focused on neuronal morphology, metabolites of the tryptophan pathway, and the neurodevelopmental
transcriptome.
Methods: The gene dosage-dependent change of QPRT expression following Chr16p11.2 deletion was investigated in a
lymphoblastoid cell line (LCL) of a deletion carrier and compared to his non-carrier parents. Expression of QPRT was tested
for correlation with neuromorphology in SH-SY5Y cells. QPRT function was inhibited in SH-SY5Y neuroblastoma cells
using (i) siRNA knockdown (KD), (ii) chemical mimicking of loss of QPRT, and (iii) complete CRISPR/Cas9-mediated knock
out (KO). QPRT-KD cells underwent morphological analysis. Chemically inhibited and QPRT-KO cells were characterized
using viability assays. Additionally, QPRT-KO cells underwent metabolite and whole transcriptome analyses. Genes
differentially expressed upon KO of QPRT were tested for enrichment in biological processes and co-regulated
gene-networks of the human brain.
Results: QPRT expression was reduced in the LCL of the deletion carrier and significantly correlated with the neuritic
complexity of SH-SY5Y. The reduction of QPRT altered neuronal morphology of differentiated SH-SY5Y cells. Chemical
inhibition as well as complete KO of the gene were lethal upon induction of neuronal differentiation, but not
proliferation. The QPRT-associated tryptophan pathway was not affected by KO. At the transcriptome level, genes
linked to neurodevelopmental processes and synaptic structures were affected. Differentially regulated genes were
enriched for ASD candidates, and co-regulated gene networks were implicated in the development of the dorsolateral
prefrontal cortex, the hippocampus, and the amygdala.
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Conclusions: In this study, QPRT was causally related to in vitro neuronal differentiation of SH-SY5Y cells and affected
the regulation of genes and gene networks previously implicated in ASD. Thus, our data suggest that QPRT may play
an important role in the pathogenesis of ASD in Chr16p11.2 deletion carriers.
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Background
Altered neuronal development is suggested to be one of
the major drivers in the etiology of autism spectrum disor-
ders (ASD). Neuropathological studies based on postmor-
tem brains of ASD patients reported aberrant neuronal
development including reduced dendritic branching in the
hippocampus [1], smaller pyramidal neurons in the lan-
guage associated Broca’s area [2], abnormal minicolumnar
organization in the cerebral cortex leading to decreased
inter-areal connectivity [3], and disorganized layers of the
cortical areas [4]. The underlying etiology of ASD is
mainly based on different genetic findings including de
novo copy number variations (CNVs). These CNVs, in
particular deletions, have been recurrently shown to alter
genic regions in ASD individuals [5], specifically affecting
neurodevelopmental genes [6].
One of the most recurrent CNVs in ASD resides
within Chr16p11.2 spanning ~ 600 kb. Overall, duplica-
tions and deletions of 16p11.2 can be identified in 0.8%
of ASD cases [7]. A deletion of this region is associated
with a nine times higher likelihood of developing ASD,
and the duplication is associated with a nine times
higher risk of both ASD and schizophrenia [8]. While
developmental delay or intellectual disability can occur
in some cases of 16p11.2 duplication carriers, they are
more common in deletions [9, 10].
The 16p11.2 CNV region spans 29 genes which
showed gene dosage-dependent expression in lympho-
blastoid cell lines (LCLs) of CNV carriers, leading to a
differential expression of genes implicated in biological
processes such as synaptic function or chromatin modi-
fication [11].
A study in zebrafish showed that the majority of the
human Chr16p11.2 homologous genes are involved in
nervous system development: loss of function of these
genes led to an altered brain morphology for 21 of 22
tested genes [12]. Double heterozygous knockouts of the
Chr16p11.2 homologs double C2 domain alpha
(DOC2A) and family with sequence similarity 57, mem-
ber Ba (FAM57BA) induced hyperactivity, increased
seizure susceptibility and increased body length and
head size in zebrafish [13]. In mice, CNVs of the hom-
ologous 16p11.2 region induced differing phenotypes.
Two studies reported the deletion to result in a reduc-
tion of the skull [14] or brain size [15], accompanied by
gene dosage-sensitive changes of behavior and synaptic
plasticity [14] as well as altered cortical cytoarchitecture,
and reduction of downstream extracellular signaling-re-
lated kinase (ERK/MAPK) effectors [15]. Comparing in-
dividual brain regions in mice with deletions to
wild-type animals, Horev and associates identified six re-
gions with an increased volume, which were not altered
in duplication carriers (see Dataset S04 in the original
publication [16]). In another study, mice carrying a het-
erozygous microduplication of the region showed
increased dendritic arborization of cortical pyramidal
neurons [17]. Via network analysis of protein-protein-in-
teraction, the authors identified the gene coding for
mitogen-activated protein kinase 3 (MAPK3) as hub
gene. MAPK3 plays a role in signaling cascades involved
in proliferation and differentiation. A recent study fo-
cused on different effects of 16p11.2 deletions in male
and female mice and reported impairments of
reward-directed learning in male mice accompanied by
male-specific overexpression of dopamine receptor D2
(DRD2) and adenosine receptor 2a (ADORA2A) in the
striatum [18]. Both genes have been discussed in the
context of ASD [19, 20].
While the functional validation of the entire CNV
models the genomic status of the patients, investigating
gene dosage effects of single genes located in
Chr16p11.2 is useful to understand their individual con-
tribution to the complex and diverse pathologies of
ASD. In zebrafish, the suppression of potassium channel
tetramerization domain containing 13 (KCTD13) was as-
sociated with macrocephaly whereas overexpression led
to microcephaly [21]. In mice, the same study showed a
reduction of KCTD13 to result in increased proliferation
of neuronal progenitors, which is also suggested to result
in macrocephaly. Further, a heterozygous deletion of the
gene coding for major vault protein (MVP) induced a re-
duction of functional synapses in mice [22]. TAO kinase
2 (TAOK2), also located in 16p11.2, was found to be es-
sential for the development of basal dendrites and
axonal projections in cortical pyramidal neurons of mice
[23]. Chr16p11.2 genes DOC2A, KIF22, and T-box 6
(TBX6) are required for the development of neuronal
polarity in mouse hippocampal cultures [24].
In ASD patients, multiple brain measures such as the
thalamic or total brain volume were reported to be
Haslinger et al. Molecular Autism            (2018) 9:56 Page 2 of 17
increased in 16p11.2 deletion carriers and reduced in
duplication carriers [25, 26]. Another study integrated
physical interactions of 16p11.2 proteins with spatiotem-
poral gene expression of the human brain. The authors
identified the KCTD13-Cul3-RhoA pathway as being
crucial for controlling brain size and connectivity [27].
Still, only few genes of the Chr16p11.2 region have been
investigated for their specific role in neuronal differenti-
ation in human models.
Here, we investigated the SH-SY5Y neuroblastoma cell
model as a well-studied and feasible model for neuronal
differentiation in vitro. Previously, we reported that a
continuous application of brain-derived neurotrophic
factor (BDNF) and retinoic acid (RA) leads to neuronal
cells of most likely cortical identity with a transcriptomic
signature reminiscent of that of neocortical brain tissue
developed for 16–19 weeks post-conception [28]. In
addition, we showed expressed genes in the differenti-
ated SH-SY5Y model to be co-regulated within modules,
several of which were associated with neurodevelopmen-
tal disorders such as the orange module. We then imple-
mented three complementary statistical methods to
identify genes that were (i) differentially regulated upon
differentiation, (ii) significantly involved in the independ-
ent processes active during differentiation and/or (iii)
that were significantly changed over time. Finally, we
described a list of 299 robustly regulated genes that
appeared to be significant in all three analyses [28].
We here report that of the 29 genes located within
Chr16p11.2, a total of 10 genes were identified by at
least one of the three implemented statistical ap-
proaches. However, only the gene coding for quinolinate
phosphoribosyltransferase (QPRT) was identified by all
three analyses. In addition, QPRT was one of the most
highly expressed genes of the Chr16p11.2 region and
showed the highest regulatory fold change (FC) after in-
duction of neuronal differentiation. Also, QPRT was
co-regulated with an early upregulated gene module
(MEorange) which showed significant enrichment for
ASD candidate genes [28].
QPRT codes for an enzyme of the kynurenine pathway,
the primary route for tryptophan catabolism, which re-
sults in the production of nicotinamide adenine di-
nucleotide (NAD+). In addition, it is the only enzyme
catabolizing quinolinic acid (QUIN), a potent excitotoxin
acting as N-methyl-D-aspartate receptor (NMDA-R)
agonist. QUIN is also linked to astroglial activation and
cell death as originally identified in the context of Alz-
heimer’s disease [29]. QPRT-KO mice showed increased
QUIN levels in the brain [30] and increased excretion of
QUIN in urine [31]. A significant increase of QUIN was
observed in blood plasma of children with ASD when
compared to their age-matched healthy control siblings
[32]. Furthermore, QPRT was identified as an interaction
partner of the ASD candidate neuroligin 3 (NLGN3;
[33]), suggesting an involvement of QPRT in the forma-
tion of the postsynaptic density.
Here, we hypothesized that QPRT is implicated in
neuronal differentiation and that reduced QPRT expres-
sion following its deletion results in alterations of neuro-
morphological development. We first tested the gene
dosage-dependent expression of QPRT in a patient-spe-
cific LCL of one Chr16p11.2 deletion carrier. We then
analyzed the expression of QPRT and its co-regulated
gene set for correlation with the development of neur-
onal morphology in SH-SY5Y wild-type (WT) cells. To
study the effects on neuronal morphology, we inhibited
QPRT function in SH-SY5Y cells using (i) siRNA knock-
down (KD), (ii) chemical mimicking of loss of QPRT,
and (iii) complete CRISPR/Cas9-mediated knock out
(KO). QPRT-KD cells underwent morphological analysis.
Chemically inhibited and QPRT-KO cells were character-
ized using viability assays. To understand the effects of
QPRT loss on the kynurenine pathway and QUIN levels,
we additionally performed a metabolite analysis of the
generated QPRT-KO cells. To explore the systems-wide
interaction network of QPRT, we investigated the tran-
scriptomic signature of QPRT-KO cells. Finally, to
understand the role of QPRT in neural development, we
tested the genes associated with QPRT-KO for enrich-
ment among gene-networks implicated in human brain
development [34].
Methods
Cellular models
Patient-specific lymphoblastoid cell lines (LCLs)
Lymphoblastoid cell lines (LCLs) were generated as pre-
viously published [35, 36]. We investigated LCLs gener-
ated from one Chr16p11.2 heterozygous deletion carrier
and his non-carrier parents. The child was diagnosed
with autism (ICD10: F84.0) based on both the Autism
Diagnostic Interview-Revised (ADI-R; [37, 38]) and the
Autism Observation Schedule (ADOS; [39]). The patient
presented with a severe impairment of social interaction,
hyperactive and aggressive behavior as well as language
delay, and an average non-verbal IQ = 90. The deletion
was identified in a screen of 710 children with ASD and
their parents using the Illumina Human OmniExpress
Microarray and validated via real-time PCR (unpub-
lished data). To investigate QPRT gene expression at
transcriptional level in exponentially growing cell cul-
tures of the Chr16p11.2 deletion carrier compared to his
non-carrier parents, 1 × 106 viable cells were inoculated
into 5 ml RPMI medium supplied with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 1X GlutaMAX (all from GIBCO®, Life Technolo-
gies, Paisley, UK). Volume was doubled when cultures
reached a density of 1 × 106 cells/ml. Finally, cells were
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harvested with a total volume of 20 ml at a density of
again 1 × 106 cells/ml. Whole RNA was extracted, including
DNase treatment, and reversely transcribed using the Gen-
eJet RNA Purification Kit and the RevertAid H Minus first
strand cDNA synthesis kit (both from Thermo Fisher Sci-
entific) following the manufacturer’s protocols. Real-time
RT-PCR was performed using the Universal Probe Library
(UPL; Roche) and a StepOne Plus device (Applied Biosys-
tems) and normalized to glucuronidase beta (GUSB; see
Additional file 1: Supplementary Methods and Table S1).
Neuroblastoma cell line SH-SY5Y
Out of possible cell types to investigate neuronal differ-
entiation, SH-SY5Y is well studied, feasible, and with an
optimized protocol shows reproducible differentiation of
cells into cortical-like neurons [28]. For proliferation,
cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS, 1% so-
dium pyruvate (all from Life Technologies), and 1%
penicillin/streptomycin (PAA). As described in our pre-
vious study [28], SH-SY5Y cells were differentiated using
a continuous application of retinoic acid (RA) and
brain-derived neurotrophic factor (BDNF). Differenti-
ation media consisted of Neurobasal®-A medium supple-
mented with 1x GlutaMAX, 1x B-27 supplement (all
from Life Technologies), 10 μM RA, 2 mM cAMP (both
from Sigma-Aldrich), 50 ng/ml hBDNF (Immunotools),
1% penicillin/streptomycin (PAA), and 20 mM KCl. Cells
were differentiated for 11 days changing the medium
every other day. The time points for extraction of
mRNA or protein and imaging were set 24 h after media
changes (0/undifferentiated cells, 1, 3, 5, 7, 9, and 11 days
of in vitro differentiation).
To study the morphological development of WT
SH-SY5Y cells during neuronal differentiation, we trans-
fected proliferating cells with pmaxGFP (Lonza) using
Metafectene Pro (Biontex) according to the manufac-
turer’s protocol. One day after transfection, cells were
seeded 1:2 in co-cultures with untransfected cells with a
density of 1 × 104 cells/cm2 to allow imaging of individ-
ual transfected cells. Cultures were imaged using a
Motic AE31 fluorescence microscope (Motic). Images
were analyzed using custom macros in ImageJ [40] avail-
able on request. In short, all images were equalized, des-
peckled, and the background was subtracted using the
rolling ball method prior to binarization (Auto threshold
“Otsu-dark”). Sholl analysis [41], a concentric circle
method, was performed using the respective ImageJ plu-
gin with manual selection of the cells’ center and with
fitting polynomial regression of the fifth degree, as sug-
gested by the manual [42]. The following morphological
parameters were assessed: maximum intersections (max-
imum number of neuritic intersections for one radius),
sum of intersections (sum of all intersections of one
cell), enclosing radius (the outer radius intersecting the
cell, describing the longest distance between soma and
neurites), intersecting radii (number of radii intersecting a
cell, also describing the distance between soma and neur-
ites), average number of intersections (the number of in-
tersections analyzed divided by the number of intersecting
radii; a measure describing neuritic complexity) and max-
imum intersections radius (the distance from the soma
where most neurites are present, i.e., the site of the highest
branching density; also reflecting neuritic complexity).
Morphological parameters have been assessed in parallel
during the previous transcriptomic analysis [28].
We made use of the previously published whole tran-
scriptome data of differentiating SH-SY5Y cells (gene ex-
pression omnibus repository (GEO) under the accession
number GSE69838 [28]) and analyzed QPRT expression
as well as regulation of modules of co-expressed genes for
correlation with the simultaneously assessed morpho-
logical parameters of SH-SY5Y neuronal differentiation
(see also the “Statistical analysis” section below). Further-
more, QPRT expression during neuronal differentiation
was validated in the same mRNA extracts using real-time
RT-PCR. RNA extraction, cDNA generation, and
real-time RT-PCR were performed as described above and
in Additional file 1: Supplementary Methods. Expression
values were normalized to GUSB and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Reduction of QPRT in neuroblastoma cell line SH-SY5Y
siRNA-mediated knockdown (KD) of QPRT
QPRT expression in SH-SY5Y was reduced using three
different siRNAs (siQ1–siQ3) and compared to a
non-targeting control siRNA (siCtrl) using the Ambion Si-
lencer Select siRNAs (Thermo Fisher; Additional file 1:
Supplementary Methods). siRNA-generated KD of QPRT
after 11 days of differentiation was proven in parallel to
the morphological analysis on protein level via Western
Blot as described in Additional file 1: Supplementary
Methods. In short, QPRT (mouse anti-QPRT, Abcam) and
control β-Actin (ACTB; mouse anti-β-Actin, Sigma) were
detected using the secondary antibody anti-mouse IgG
HRP-conjugated (Santa Cruz), the ECL Prime Western
Blot Detection Reagent, and the Amersham Hyperfilm
ECL (both from GE Healthcare). To allow imaging of
fluorescent single cells in order to study morphological ef-
fects of QPRT knockdown, we co-transfected SH-SY5Y
cells with mCherry (Plasmid #30125; Addgene). In a
96-well format, 5.2 × 104 cells/cm2 were reversely trans-
fected with 120 ng of mCherry and 5 nM siRNA using Li-
pofectamine RNAi Max and OptiMEM (Thermo Fisher).
CRISPR/Cas9 mediated knock out (KO) of QPRT
CRISPR/Cas9 gene editing was performed as described
elsewhere [43]. In short, sgRNAs were designed [44] and
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oligos were ordered from Sigma-Aldrich and cloned into
pSpCas9(BB)-2A-Puro (PX459) V2.0 (Plasmid #62988;
Addgene). Two sgRNAs targeting different sequences of
QPRT were designed to generate homozygous knock out
in addition to the non-targeting empty control vector
(see Additional file 1: Supplementary Methods and
Supplementary Results). Validated plasmids (Sanger se-
quencing) were transfected into SH-SY5Y cells using
Metafectene Pro (Biontex) according to the manufac-
turer’s protocol with subsequent puromycin (Sigma-Al-
drich) selection using 750 ng/ml for 7 to 14 days. After
low-density seeding, single clones were isolated using
5 μl of Trypsin-EDTA (Thermo Fisher Scientific) and ex-
panded in 96-well plates. Overall, we sequenced at least
ten clones per construct and confirmed homozygous sin-
gle cell clones at least twice by Sanger sequencing in-
cluding the empty control vector. Clones were named as
follows: del268T (QPRT NM_014298 del268T; Ex2.1),
ins395A (QPRT NM_014298 ins395A; Ex2.2), eCtrl
(empty control vector). Both indels induced premature
stop codons as validated in silico and by Sanger sequen-
cing. KO of QPRT was further shown on RNA and
protein level using real-time RT-PCR and Western Blot,
respectively. RNA extraction, cDNA generation, and
real-time RT-PCR as well as protein extraction and West-
ern Blots were performed as described above and in
Additional file 1: Supplementary Methods. RNA expres-
sion values were normalized to GUSB and GAPDH, and
protein expression was descriptively compared to GAPDH
expression.
Functional analyses in neuroblastoma cell line SH-SY5Y
siRNA-mediated KD of QPRT
The day after transfection (see above), media were chan-
ged from proliferation to differentiation media. After
changing the media every other day for a time course of
11 days, cells were imaged using an ImageXPress Micro
XLS (Molecular Devices). Images were pre-processed in
MetaXPress and analyzed in ImageJ using Sholl analysis
(as described above).
Chemical mimicking of QPRT loss
To measure the effect of chemical QPRT inhibition, we
seeded WT SH-SY5Y cells with a density of 2.5 × 104
cells/cm2. After cells have attached overnight, media
were changed to either fresh proliferation or differenti-
ation media containing 0 (reference), 5, or 10 mM of the
QPRT inhibitor phthalic acid (PA; Sigma; directly diluted
in the respective media; [45]) and incubated for 3 days
followed by propidium iodide (PI) viability assays. PI and
Hoechst33342 (both from Sigma) were pre-diluted in
DPBS (Life Technologies) and used with final concentra-
tions of 1 μg/ml and 10 μg/ml for the assay, respectively.
Prior to analysis, supernatant including detached and
dead cells was removed and attached cells were washed
with DPBS. Next, attached cells were incubated with PI
and Hoechst33342 for 5 min at 37 °C and imaged using
the ImageXPress Micro XLS microscope (Molecular De-
vices). Images were acquired through DAPI and TRITC
channels and analyzed using the MetaXPress macro
“Cell Scoring”. Percentage of dead cells after application
of 5 and 10 mM PA was compared to the 0 mM
reference for proliferating and differentiating cells,
respectively.
To test if the observed cell death upon chemical inhib-
ition of QPRT during differentiation is driven by an accu-
mulation of the QPRT substrate quinolinic acid (QUIN;
Sigma), we exposed WT cells to this neurotoxin. Cells
were seeded with a density of 2.5 × 104 cells/cm2 and
media were changed after 24 h to either fresh proliferation
or differentiation media containing 0 (reference; vehicle
H2O only), 5, or 250 μM of QUIN [46] and incubated for
3 days followed by PI viability-assays (as described above).
Percentage of dead cells after application of 5 and 250 μM
QUIN was compared to the 0 μM reference for proliferat-
ing and differentiating cells, respectively.
CRISPR/Cas9-mediated KO of QPRT
Viability assay To measure the effect of QPRT-KO on
the viability of differentiating SH-SY5Y, KO and eCtrl
cells were seeded at a density of 2.5 × 104 cells/cm2. The
following day, media were changed to differentiation
media. After 3 days, PI viability-assays were performed
(as described above).
Rescue experiments of QPRT-KO cells We further
aimed to rescue the effects of a potential QPRT-KO-dri-
ven increase of QUIN by inhibiting downstream path-
ways. Cells were seeded with a density of 2.5 × 104 cells/
cm2. After 24 h, media were changed to differentiation
media containing (i) 0 (reference; vehicle H2O only), 6,
and 12 μM of the NMDA-R antagonist MK801 [47], (ii)
0 (reference; vehicle H2O only), 0.5, and 1 mM of nitric
oxide synthase 1 (NOS1) inhibitor L-NAME [48], and
(iii) 0 (reference; vehicle H2O only), 5, and 10 mM of
NAD+ [49]. PI viability assays were performed after an
incubation of 3 days (as described above). All rescue ex-
periments were performed with differentiating QPRT-KO
cell lines compared to the eCtrl.
Metabolite analysis To characterize QPRT-KO at the
level of the kynurenine pathway, i.e., tryptophan catabolism,
we analyzed its metabolites in cell culture supernatants
using ultra-high-performance liquid chromatography
(UHPLC; for tryptophan (TRP), kynurenine (KYN),
3-hydroxykynurenine (3HK), 3-hydroxyanthranilic acid
(3HAA), anthranilic acid (AA) and kynurenic acid (KA)),
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and gas chromatography-mass spectrometry (GC/MS; for
picolinic acid (PIC) and QUIN). Cell lines were seeded with
a density of 2 × 104 cells/cm2 and grown in proliferation or
differentiation media for 3 days as described above. Super-
natants of replicates were harvested and stored at − 80 °C
until further proceedings. UHPLC and GC/MS were
performed as described previously [32, 50] (see also
Additional file 1: Supplementary Methods).
Massive analysis of cDNA ends (MACE) To investi-
gate the transcriptomic changes induced by QPRT-KO,
we performed a whole transcriptome analysis using the
RNA-Seq approach MACE. MACE sequencing in con-
trast to RNA sequencing reads cDNA ends only rather
than whole transcripts, i.e., poly-A tails. The output
values of MACE-Seq are absolute counts per cDNA end.
This approach is more sensitive compared to classical
RNA-Seq. This method allows the detection of low
abundant transcripts and differentiation between alter-
native 3′UTRs with high accuracy [51, 52]. However, it
does not allow to identify alternative exon usage.
Cell lines (three biological replicates of each WT,
eCtrl, and KO cells) were seeded with a density of 2 ×
104 cells/cm2 in proliferation medium. After 3 days,
media were changed to differentiation and cells were dif-
ferentiated for 3 days without media changes. RNA was
prepared as described above. RNA integrity number
(RIN) was analyzed using the LabChip GX system and
only samples with RINs above 9.7 underwent further
analysis. MACE analysis including quality control was
outsourced to GenXPro (Frankfurt) [53]. Reads were
mapped to the human genome version hg38 using the
Bowtie2 algorithm implementing the “--sensitive-local”
parameter and standard settings as published [54].
A total of 12 genes found to be significantly differen-
tially expressed in KO cells with an absolute log2 fold
change (FC) above 2.5 were chosen for validation via
real-time RT-PCR using the UPL system as described
above with GAPDH, GUSB, and proteasome 26S subunit,
non-ATPase 7 (PSMD7) as housekeeping genes. Add-
itionally, the GOIs QPRT, nicotinamide nucleotide ade-
nylyltransferase 2 (NMNAT2; only downstream enzyme
of QPRT differentially regulated upon KO of QPRT), and
NLGN3 were included for validation (Additional file 1:
Table S1).
Statistical analysis
If not stated otherwise, statistical analyses were per-
formed using R version 3.2.3.
Group differences
Group differences between mRNA expression in LCLs of a
deletion carrier compared to his non-carrier parents were
tested using t test. Group differences of morphological
parameters were tested using ANOVA and pairwise
ANOVA (type III error) with Tukey’s honest significant dif-
ference (HSD) correcting for multiple testing; Tukey’s FDRs
were considered significant below a threshold of FDR ≤
0.05. Group differences between treated and untreated
samples (e.g., PI assays) were tested using t test; uncor-
rected p values are reported. All samples were compared to
their respective control (e.g., non-targeting siRNA) or
reference (e.g., 0 mM of inhibitor).
Correlations
Correlation between morphological parameters and gene
expression or eigengene expression was tested based on
the Pearson’s product moment correlation coefficient
following a t-distribution. Reported p values are Bonfer-
roni corrected for 126 tests (6 morphological parame-
ters, 20 gene modules, 1 gene expression).
Targeted mRNA expression
Data of real-time RT-PCR experiments were analyzed
using the 2ΔΔCt method [55]. Group differences were
tested using t test. For validation of RNA-Seq data,
real-time RT-PCR data and RNA-Seq (MACE) normal-
ized reads were tested for correlation as described above
using Pearson’s correlation tests.
Transcriptome analysis
Overall 32,739 transcripts were targeted by MACE ana-
lysis and defined as the gene universe (reference gene
panel). Differentially expressed genes were identified
using the “DESeq2” pipeline [56] with the gene expres-
sion as the dependent variable and the respective groups
as the independent variable. No additional covariates
have been included since the samples did not differ with
respect to RIN, number of total counts, or batch. Hier-
archical cluster analysis using the top 2000 genes based
on variance was performed to exclude any technical
outlier samples (for detailed quality checks see
Additional file 1: Figure S6). Four different cell lines
underwent MACE analysis: the untreated wild-type
(WT), the empty control vector (eCtrl), the KO cell line
QPRT−/− del268T, and the KO cell line QPRT−/−
ins395A. Three technical replicates were sequenced for
each cell line. Differential gene expression induced by
QPRT-KO was assessed by comparing (i) WT vs eCtrl,
(ii) eCtrl vs KO del268T as well as (iii) eCtrl vs KO
ins395A independently. A gene was considered to be sig-
nificantly associated with QPRT-KO if (i) no significant
change was identified between the WT and the eCtrl cell
line (FDR > 0.1), (ii) if a significant (FDR < 0.05) differ-
ence was observed between both the eCtrl and KO
del268T and between eCtrl and KO ins395A, and (iii)
the direction of the effect was the same in both of the
comparisons eCtrl vs KO del268T and eCtrl vs KO
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ins395A, respectively. For the differential expression
analysis between two groups, raw counts of the respect-
ive replicates were loaded into DESeq2 using the
“DESeqDataSetFromMatrix” function. Differential ex-
pression was estimated using the function “DESeq” with
the option “fitType = ‘local’”. Significantly up and
downregulated genes underwent GO term analysis
(Additional file 1: Supplementary Methods). Genes
surviving quality check (more than 10 reads per gene in
at least 6 of the 12 samples) were subjected to weighted
gene co-expression network analysis (WGCNA;
Additional file 1: Supplementary Methods).
Gene list enrichment test in gene networks of brain
development
To gain a deeper insight into the brain-specific effects of
up and downregulated genes from MACE analysis, we
used part of a framework proposed by Yousaf et al. [57].
In short, this framework uses the Allen Brain Atlas data-
set of Kang and colleagues, who have identified 29
co-regulated gene sets using the spatiotemporal tran-
scriptome of the human brain from early embryonal
development to late adulthood [34]. Each module corre-
sponds to specific biological processes involved in brain
development and aging. We tested these modules for en-
richment with the sets of genes up or downregulated
upon QPRT-KO in SH-SY5Y using Fisher’s exact tests.
Expression patterns of the enriched modules were then
visualized using heatmaps of the eigenvalues of the
respective modules for each human brain region over
time.
Results
Patient-specific lymphoblastoid cell lines (LCLs)
To replicate previous reports [11] of altered QPRT ex-
pression in 16p11.2 CNV carriers, we compared QPRT
expression in a patient-specific LCL of a deletion carrier
and his unaffected parents. We confirmed a dosage
dependent expression of QPRT at mRNA level (16p11.2
deletion carrier vs. non-carrier parents; logFC = − 0.68,
p = 0.014; Additional file 1: Figure S1a).
Correlation of QPRT and neuritic complexity in SH-SY5Y
wild-type cells
RNA expression of QPRT during SH-SY5Y differentiation
significantly correlated between microarray [28] and
real-time RT-PCR (ρ = 0.88; p = 0.0098; Additional file 1:
Figure S1b). Further, we used the expression data of QPRT
as well as of the modules of genes co-regulated during
neuronal differentiation and tested them for their correl-
ation with morphological parameters using Sholl analysis
during 11 days of neuronal differentiation (Additional file 1:
Figure S1c and d). Both QPRT expression and the eigen-
value of its associated module (MEorange) significantly
correlated with the average number of intersections
(QPRT microarray: ρ = 0.86, FDR = 8.16E−05; QPRT
RT-PCR: ρ = 0.54, FDR = 0.020; MEorange: ρ = 0.93, FDR
= 1.71E−07; Additional file 1: Figure S1d).
In summary, we report a correlative association be-
tween QPRT expression and a measure for the develop-
ment of neurite complexity during in vitro neuronal
differentiation of wild-type SH-SY5Y cells. To investigate
if the correlation of QPRT expression with neuritic com-
plexity is causal or secondary, i.e., due to the progressive
neurite growth over time, we performed functional in-
hibition analysis of QPRT.
Functional validation in neuroblastoma cell line SH-SY5Y
siRNA mediated knockdown (KD) of QPRT
All three siRNAs targeting three different sites of QPRT
(named here siQ1–siQ3) induced a decrease in QPRT pro-
tein after 11 days of differentiation as confirmed by West-
ern Blot (Fig. 1a). At neuromorphological level, KD cell
lines compared to control cell lines (siCtrl) showed a sig-
nificant decrease of the maximum intersections radius, al-
tering neuritic complexity in that the site of highest
branching density was shifted closer towards the soma (p
siQ1 0.027, siQ2 0.001, siQ3 3.8E−04; means [SD] siCtrl
103.98[115.54]; siQ1 56.50[80.53]; siQ2 56.29[97.17]; siQ3
41.51[76.70]). The overall cell size or the enclosing radius,
did not change upon KD of QPRT (all p > 0.6; means [SD]
siCtrl 349.60[223.68]; siQ1 286.98[125.05]; siQ2 270.06
[135.62]; siQ3 293.81[176.86]; Fig. 1a; Additional file 1:
Figure S2).
Mimicking of QPRT loss
Cells exposed to an inhibitor of QPRT, the chemical
phthalic acid (PA), showed an increased cell death upon
induction of differentiation, and thus no end-point mor-
phological analysis was performed. Application of PA for
3 days led to a dosage-dependent increase of cell death
during differentiation (5 mM PA: FC = 1.81, p = 0.019;
10 mM PA: FC = 4.21, p = 0.039) but not during prolifer-
ation (5 mM PA: FC = 0.73, p = 0.432; 10 mM PA: FC =
0.68, p = 0.355; Fig. 1b).
We further hypothesized that inhibition of QPRT
might lead to increased levels of its neurotoxic substrate
quinolinic acid (QUIN). Thus, we exposed wild-type
cells to elevated QUIN levels. However, we did neither
observe an increase in cell death during proliferation (all
p > 0.3 for 5 μM and 250 μM QUIN) nor during
differentiation (all p > 0.3 for 5 μM and 250 μM QUIN;
Additional file 1: Figure S5a) compared to vehicle only
(0 μM). Since the findings from chemical inhibition and
mimicking of QPRT inhibition suggested that QPRT is
causally linked to differentiation deficits independent of
its substrate QUIN, we aimed at elucidating the
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Fig. 1 Functional analysis of QPRT in SH-SY5Y cells. a siRNA-mediated knockdown (KD) of QPRT. Cells were transfected with a non-targeting siRNA
(siCtrl) and three different siRNAs targeting QPRT (siQ1–siQ3). Transfected cells were differentiated for 11 days followed by morphological analysis.
Knockdown of QPRT was confirmed at protein level. Upon QPRT-KD, cells showed a significant decrease of the maximum intersections radius
when compared to the non-targeting control, i.e., the maximum complexity of neurites was significantly closer to the cell soma. None of the
three KDs differed with respect to the enclosing radius when compared to the non-target control, i.e., the length of the neurites was not different
(Additional file 1: Figure S2). Maximum intersections radius: radial distance of the maximum number of intersections from the cell body. Enclosing
radius: outer radius intersecting the cell. All p values were corrected for multiple testing using Tukey's HSD correction. b Chemical inhibition
of QPRT. Application of the QPRT inhibitor phthalic acid (PA) for 3 days led to a dose-dependent significant increase of cell death in differentiating
wild-type SH-SY5Y cells. In proliferating cells, QPRT inhibition did not change the rate of cell death. c Viability assays of CRISPR/Cas9 mediated QPRT-
knock out (KO) cells. Percentage of cell death was assessed performing viability assays after 3 days of differentiation showing a significant increase of
cell death in both generated QPRT-KO cell lines. d Representative images of QPRT-KO cells after differentiation. KO of QPRT led to observable cell death
during 9 days of differentiation but not during proliferation
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underlying processes in SH-SY5Y cells with a stable loss
of QPRT.
CRISPR/Cas9 mediated knock out (KO) of QPRT
Generation and viability Using two separate sgRNA se-
quences (see Additional file 1: Supplementary Methods
and Supplementary Results), we generated two homozy-
gous QPRT-KO cell lines, del268T and ins395A
(NM_014298), both of which showed a nearly complete
loss of expression of QPRT mRNA expression (prolifer-
ating cell lines: del268T: below detection limits, ins395A:
FC = 0.17, p = 0.046; 2 days of differentiation: del268T:
FC = 0.13, p = 0.003; ins395A: FC = 0.15, p = 0.003; all
compared to the proliferating empty control vector
(eCtrl); Additional file 1: Figures S3 and S4). For prolif-
erating cells, QPRT-KO was furthermore descriptively
confirmed at protein level (Additional file 1: Figure S4).
While the eCtrl and both QPRT-KO cell lines were
growing comparably during proliferation, both KO cell
lines died upon differentiation. After 3 days of differenti-
ation, we observed a significant increase of cell death in
the KO cell lines when compared to eCtrl cells harbor-
ing the empty control vector (eCtrl to del268T: FC =
2.23, p = 8.2E−04; eCtrl to ins395A: FC = 1.76, p = 5.2E
−04; Fig. 1c), and after 9 days of differentiation, merely
no differentiating KO cells were detected under the
microscope (Fig. 1d).
Rescue experiments using small compounds We tried
to rescue the QPRT-KO effect by inhibiting the effector
pathways downstream of QUIN, i.e., inhibit a potentially
induced neurotoxicity by hyperactivation of NMDA-R as
well as replenish NAD+, which is the downstream me-
tabolite of QPRT as well as the final outcome of the
kynurenine pathway. Neither the NMDA-R antagonist
MK801 (both QPRT-KO compared to eCtrl: FC > 1.7, p
< 3.9E−03 for 0 μM; FC > 1.6, p < 0.04 for 6 μM; FC >
1.6, p < 1.5E−03 for 12 μM) nor the inhibition of the
NMDA-R downstream enzyme NOS1 by L-NAME (both
QPRT-KO compared to eCtrl: FC > 1.3, p < 0.05 for
0 mM; FC > 1.3, p < 0.02 for 0.5 mM; FC > 1.5, p < 0.01
for 1 mM) nor supplying NAD+, the downstream prod-
uct of tryptophan catabolism (both QPRT-KO compared
to eCtrl: FC > 1.3, p < 9E−03 for 0 mM; FC > 1.3, p < 1.6E
−03 for 5 mM; del268T compared to eCtrl: FC = 1.20, p
= 0.1; ins395A compared to eCtrl: FC = 1.54, p = 0.009
for 10 mM), resulted in a significant reduction of cell
death for both of the KO cell lines upon differentiation
(Additional file 1: Figure S5b).
Metabolite analysis To test if the loss of QPRT results
in an altered metabolite profile of the kynurenine path-
way, we implemented UHPLC and GC/MS analysis. We
were able to detect tryptophan (TRP), kynurenine
(KYN), kynurenic acid (KA), 3-hydroxykynurenine
(3HK), anthranilic acid (AA), and picolinic acid (PA).
QUIN could not be detected in any of the samples, while
3-hydroxyanthranilic acid (3HAA) could only be de-
tected in the differentiated (eCtrl and both of the KO)
cell lines only. However, no significant changes could be
observed in any of the metabolites when comparing both
of the QPRT-KO cell lines to the control cell lines
(Additional file 1: Figure S5c).
MACE transcriptome analysis of QPRT-KO Since in
our cell model the effect of QPRT-KO on neuronal
differentiation was not related to changes in the kynure-
nine pathway or the neurotoxic effects of QUIN, we
aimed to further elucidate the effect of the KO on
differentiating cells implementing a transcriptome-wide
analysis. Overall, we were able to measure the expression
of 32,739 transcripts (Additional file 2: Table S2).
Statistical analysis identified 269 differentially regulated
genes (103 upregulated and 166 downregulated; Fig. 2a;
Additional file 2: Table S2) expressed in all three repli-
cates of both KO cell lines, all with an FDR ≤ 0.05. The
12 genes (Table 1) with an absolute log2FC > 2.5 were
technically validated using real-time RT-PCR with an
average correlation between RNA sequencing data and
real-time RT-PCR of ρ = 0.91 (SD = 0.10). QPRT-KO was
also confirmed (eCtrl vs del268T: log2FC = − 2.44, FDR
= 1.07E−207; eCtrl vs ins395A: log2FC = − 3.17, FDR =
9.88E−291). Of the genes coding for components of the
kynurenine pathway, only NMNAT2 was significantly
downregulated upon QPRT-KO (eCtrl vs del268T: log2FC =
− 0.70, FDR = 2.10E−07; eCtrl vs ins395A: log2FC =− 1.51,
FDR = 6.70E−28). The ASD-implicated protein NLGN3 was
differentially downregulated in the del268T only (eCtrl vs
del268T: log2FC =− 0.43, FDR = 6.58E−02; eCtrl vs ins395A
log2FC= − 0.09, FDR = 9.15E−01) and was thus not consid-
ered to be regulated upon KO of QPRT.
The genes upregulated upon KO of QPRT were
enriched (all p values < 0.05, Fig. 2b; Additional file 3:
Table S3) for GO annotated biological processes in-
volved in neurotransmitter secretion, regulation of syn-
apse structure, or activation (Fig. 2b) but also negative
regulation of cell growth and negative regulation of cyto-
skeleton organization among others (Additional file 3:
Table S3). In addition, upregulated genes were enriched
for the GO term apoptotic process involved in morpho-
genesis via the genes BCL2 antagonist/killer 1 (BAK1)
and scribbled planar cell polarity protein (SCRIB). Genes
downregulated in KO cell lines showed enrichment for
GO terms including synapse organization, modulation of
excitatory postsynaptic potentials, or glutamate secretion
(Fig. 2b) or positive regulation of neuron differentiation,
positive regulation of dendritic spine development as
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well as ion transmembrane transport (Fig. 2b;
Additional file 3: Table S3). We also observed significant
enrichment for ASD genes among highly differentially
regulated candidates. Of the 269 differentially regulated
genes, 15 were listed in the SFARI gene [58] with an
evidence score of 4 or better (p = 9.2E−04, odds ratio
OR [95% confidence interval] = 2.68 [1.47–4.54]), for
example gamma-aminobutyric acid type A receptor
beta 3 subunit (GABRB3), potassium voltage-gated
channel subfamily Q member 3 (KCNQ3), syntrophin
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Fig. 2 Whole transcriptome analysis of QPRT-KO cells and control cell lines. a Heatmap of differentially expressed genes. Upon KO of QPRT, 269
genes were significantly differentially expressed between both of the KO and the eCtrl cell line (FDR≤ 0.05) but not between the controls (wild-
type and eCtrl, FDR > 0.1). Overall, ins395A descriptively shows stronger effects than del268T. b GO term enrichment for differentially regulated
genes. Upregulated genes were associated with GO terms including neurotransmitter secretion, negative regulation of cell growth and negative
regulation of cytoskeleton organization (all p < 0.05; Additional file 3: Table S3). Genes downregulated upon QPRT-KO were enriched for GO terms
involved in processes of neuronal development (positive regulation of neuron differentiation, positive regulation of dendritic spine development,
and synapse organization (all p < 0.04)) and neurotransmitter transport (potassium transport, as well as glutamatergic processes like glutamate
secretion and regulation of glutamate receptor signaling pathway (all p < 0.05)). Deregulated genes were enriched for processes like neurotransmitter
secretion and brain development (all p < 0.05; Additional file 3: Table S3). All p values account for the hierarchical structure of the gene ontology (GO)
and can thus be considered as corrected for multiple testing. c Regulation of the dark grey gene set. This module was identified as QPRT-KO associated
module harboring genes downregulated upon QPRT-KO when comparing both KO cell lines to wild-type and eCtrl cells (all p < 8E−07).
GO term enrichment analysis of this module again revealed processes involved in brain development and synaptic transmission and
plasticity (p < 0.05), confirming the association of QPRT-KO with neuronal development
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gamma 2 (SNTG2), or contactin associated
protein-like 2 (CNTNAP2).
A total of eleven out of 166 downregulated genes and
one gene of 103 upregulated genes showed a |log2FC| >
2.5 (Table 1). Literature search for these twelve highly
regulated genes revealed that six had been published in
the context of ASD before (Table 1).
Gene network analysis At gene network level, we identi-
fied 20 co-regulated modules upon KO. Here, QPRT was
co-regulated within a module associated with modulation
of synaptic transmission, synaptic vesicle exocytosis, or
limbic system and diencephalon development (Fig. 2c) as
well as neurotransmitter secretion or negative regulation
of neurogenesis (p < 0.04). Overall, the eigenvalue of this
module was not different between controls and KOs. We
identified one co-regulated gene set (dark grey, Fig. 2c) to
be associated with QPRT-KO as it was significantly down-
regulated in both KO cell lines when compared to the
control cell lines (KOs versus eCtrl or WT, all p < 8E−07).
GO term enrichment analysis of this module again re-
vealed processes involved in brain development and syn-
aptic transmission and plasticity (p < 0.05; Fig. 2c;
Additional file 3: Table S3), confirming the association of
QPRT-KO with neuronal development.
Translation to developmental brain expression data
Finally, we aimed to translate the effects of QPRT-KO
onto the spatial and temporal gene expression network
of the brain using previously published data [34]. In this
previous work, the authors report 29 gene modules
(termed “Kang-Module” in the following) that are
co-regulated during the development of human brain
regions. We observe that the QPRT-KO-induced down-
regulated genes were strongly enriched in the Kang-
Modules number 1 (odds ratio OR [95% confidence
interval] = 8.86 [3.12–20.45], p = 5.76E−04), number 2
(OR = 5.96 [3.55–9.75], p = 2.21E09), number 10 (OR =
69.92 [20.70–188.44], p = 2.64E−07), number 15 (OR =
14.58 [6.00–30.72], p = 1.57E−06) and number 20 (OR =
7.13 [4.40–11.40], p = 7.74E−13) while the QPRT-KO up-
regulated genes were enriched in Kang-Modules number
2 (OR = 23.20 [11.25–49.97], p = 1.07E−16) and number
20 (OR = 3.54 [1.46–7.76], p = 4.18E−02). Kang-Module
17 was enriched for QPRT-KO-induced deregulated
genes in general, i.e., for the merged lists of up and
downregulated genes (OR = 20.41 [2.33–82.57], p = 2.45E
−02; Fig. 3a). By plotting the eigengene value of the
Kang-Module over time for each region, we observed
that number 1 shows strong early upregulation in the
hippocampus (HIP) and the amygdala (AMY) during
embryonal development while it is downregulated in all
tested brain regions after birth (Fig. 3b). Kang-Module 1
is also slightly upregulated in embryonal development in
parts of the frontal cortex (orbitofrontal cortex (OFC),
dorsolateral prefrontal cortex (DFC) and medial
prefrontal cortex (MFC)), the striatum (STR), and the
cerebellar cortex (CBC). Kang-Module 2 is overall
Table 1 Differentially expressed genes upon QPRT-KO with |log2FC| > 2.5
Gene Chr del268T vs eCtrl ins395A vs eCtrl WT vs eCtrl SFARI
score
ASD literature
FDR log2FC FDR log2FC FDR log2FC
COX17 3q13.33 3.33E
−138
− 5.94 1.78E
−154
− 5.63 0.30 − 0.13 / /
GUCA1A 6p21.1 4.56E−41 − 5.38 3.97E−46 − 5.88 0.20 0.26 / /
COX17P1 13q14.13 1.09E−84 − 5.19 5.82E−93 − 5.28 0.59 − 0.11 / /
VSTM2A 7p11.2 1.81E−10 − 5.00 6.36E−12 − 5.28 0.61 − 0.27 / /
KCNQ3 8q24.22 5.77E−04 − 4.76 1.25E03 − 3.04 0.46 0.49 3 Role for KCNQ3 in epilepsy and autism [75]
CCK 3p22.1 2.56E−04 − 3.18 5.97E−05 − 3.13 0.17 0.68 / Candidate gene for Asperger’s in a microdeletion case study [76]
GABRB3 15q12 3.04E−43 − 3.00 9.43E−54 − 3.58 0.80 0.04 2 CNV Chr15q11-13 implicated in ASD; polymorphisms associated
with ASD [62, 77]
BRINP1 9q33.1 8.93E−09 − 2.92 2.09E−09 − 2.85 0.20 − 0.53 / −/− mice: autism-like behavior including reduced sociability and
altered vocalization [78]
LINC01760 1p21.3 1.02E−02 2.74 4.93E−03 2.62 0.95 − 0.30 / /
SNTG2 2p25.3 7.04E−04 − 2.71 5.06E−07 − 5.58 0.72 0.22 4 Region linked with ID [64], associated with ASD [65]; interaction
partner of neuroligins, interaction altered by ASD associated
mutations [66]
ARHGAP20 11q23.1 1.63E−09 − 2.65 4.08E−15 − 3.93 0.45 − 0.30 / /
SRRM4 12q24.23 1.29E−18 − 2.61 2.25E−26 − 3.40 0.54 − 0.20 / −/+ mice: multiple autistic-like features [79]
Chr chromosomal region, del268T CRISPR/Cas9 induced mutation (deletion of one nucleotide) in exon 2 of QPRT, ins395A CRISPR/Cas9-induced mutation (insertion
of one nucleotide) in exon 2 of QPRT, eCtrl control cell line with empty CRISPR/Cas9 control vector, WT wild-type SH-SY5Y cell line untreated, FDR False discovery
rate, log2 FC log2 fold change, SFARI score score in the SFARI database [58] (a smaller score means higher evidence), ASD references Pubmed was searched for
“gene and autism” and “gene and ASD”
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downregulated prenatally and shows upregulation
after birth, with maximum expression between the
ages of 6 and 14, i.e., during middle and late child-
hood in OFC, MFC, posterior inferior parietal cortex
(IPC), primary auditory (A1) cortex (A1C), inferior
temporal cortex (ITC), primary visual (V1) cortex
(V1C), and STR. Kang-Module 10 is only expressed
in the CBC with a peak around the age of 6 years,
while Kang-Module 15 is strongly downregulated
during embryonal development in the CBC. The low
expression of Kang-Module 15 in the CBC is stable
across the tested time course, and it is slightly up-
regulated in other brain regions, showing peaks be-
tween the years 6 and 14 in OFC, DFC, ventrolateral
prefrontal cortex (VFC), MFC, IPC, A1C, ITC, and
V1C. Kang-Module 17 shows a constant active
expression in the CBC over time with a peak during
early development in the CBC. Kang-Module 20 is
an overall early upregulated gene network downregu-
lated after the age of ~ 2 years, showing the
strongest downregulation between the years 6 and 14
in OFC, MFC, IPC, A1C, ITC, V1C, and STR.
Discussion
Based on our differential analysis, we report a causal re-
lation between QPRT, located in the ASD-associated
CNV region Chr16p11.2 and neuronal differentiation of
SH-SY5Y cells. A gene dosage reduction or inhibition of
QPRT affects morphological parameters during neuronal
differentiation as well as the regulation of genes and
gene networks that were previously implicated in ASD.
This includes processes like synapse organization or
brain development. In summary, our findings suggest a
neurodevelopmental role for QPRT in the etiology of
ASD in 16p11.2 deletion carriers.
As expected from previous findings [11], in one
deletion carrier with ASD, we confirmed that QPRT
was expressed in a gene dosage-dependent manner
strengthening the role of QPRT as a potential risk gene
in the pathology of Chr16p11.2 deletion syndrome. By
Fig. 3 Translation of QPRT-KO-induced gene expression profile to human brain development. a Modules enriched for QPRT-KO de-regulated
genes. A total of 29 modules (in the following termed “Kang-Modules”) identified by Kang and colleagues [34] were tested for enrichment with
genes differentially regulated in QPRT-KO cells. Downregulated genes were strongly enriched in the Kang-Module number 1, 10, 15, and 20 while
upregulated genes were enriched in Kang-Module 2 number and 20. Kang-Module number 17 was enriched for deregulated genes in general,
i.e., for the merged lists of up and downregulated genes. b Regulation of modules enriched for QPRT-KO implicated genes during brain
development. Kang-Modules number 15 (enriched for QPRT-KO induced downregulated genes), 2, and 20 (both enriched for genes up and
downregulated) are strongly regulated during early infancy (~ 2 years), especially in the dorsolateral prefrontal cortex, the superior temporal
cortex, hippocampus, and amygdala. Kang-Module number 10 is downregulated in the cerebellum while it is enriched for genes downregulated
in QPRT-KO cells. Kang-Module number 17 is enriched for deregulated genes and shows an upregulation of genes expressed in the cerebellum.
Kang-Module number 1 shows strong regulation of hippocampus and amygdala, parts of the frontal cortex, and the cerebellum. This module is
enriched for genes downregulated in QPRT-KO cells. Abbreviations: OFC orbital prefrontal cortex, DFC dorsolateral prefrontal cortex, VFC
ventrolateral prefrontal cortex, MFC medial prefrontal cortex, M1C primary motor (M1) cortex, S1C primary somatosensory (S1) cortex, IPC
posterior inferior parietal cortex, A1C primary auditory (A1) cortex, STC superior temporal cortex, ITC inferior temporal cortex, V1C primary visual
(V1) cortex, HIP hippocampus, AMY amygdala, STR striatum, MD mediodorsal nucleus of the thalamus, CBC cerebellar cortex
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comparing our previously published transcriptome data
of SH-SY5Y wild-type cells [28] to the morphological
changes during neuronal differentiation described in
the present study, we found QPRT to be correlated with
the development of the neuritic complexity. These re-
sults suggest a potential regulatory link between QPRT
and neuronal maturation. Our findings of the KD and
KO cell models further underline this interpretation:
the KD of QPRT led to subtle changes of SH-SY5Y
neuronal complexity in line with previous reports using
mouse models of Chr16p11.2 [17] as well as iPS cells
generated from 16p11.2 CNV carriers [59] and post-
mortem studies of ASD individuals [1]. Inhibition of
QPRT activity as well as genetic KO both led to cell
death of differentiating but not proliferating cells.
These findings suggest that enough protein is left for
the survival of differentiating cells upon KD of QPRT
while the loss of QPRT is lethal for differentiating
SH-SY5Y cells. Interestingly, the administration of the
QPRT substrate QUIN, which is a potent excitotoxin,
did not show any effect on neither proliferating nor dif-
ferentiating cells. Previous findings suggested that a re-
duction of QPRT, the only enzyme catabolizing
quinolinic acid (QUIN), leads to an accumulation of
QUIN, which in turn may induce neuronal cell death
by over-activating NMDA-R and increase nitric oxide
(NO) production [46]. Altered QUIN levels could also
lead to a change in NAD+ production which in turn
could change poly (ADP-ribose) polymerase (PARP) ac-
tivity [60]. In QPRT-KO mice, the striatum showed an
accumulation of QUIN leading to neurodegeneration
[30] as well as altered expression of enzymes of the
kynurenine pathway and of NMDA-receptors. No
ASD-like behaviors were studied in these mice, but the
animals showed no growth or developmental abnormal-
ities. As the kynurenine pathway was associated with
Parkinson’s disease [61], the authors performed a be-
havioral test measuring the stride length of WT and
KO mice. Indeed, they reported shorter stride lengths
in aged but not middle-aged QPRT-KO mice as usually
seen in mouse models of Parkinson’s disease [30]. In
another study, no differences of histological features of
the cerebrum of QPRT-KO mice were observed [31].
Although we were not able to mimic QPRT loss in WT
cells by application of increased QUIN levels, we tried to
rescue differentiating QPRT-KO cells from cell death dur-
ing differentiation by modulation of QUIN-related metab-
olism and signaling. Inhibition of NMDA-receptors was
expected to protect QPRT-KO cells from the possible
QUIN-induced excitotoxicity. However, the application of
different concentrations of an NMDA-R inhibitor did not
prevent cell death. Similarly, inhibition of NOS1 with the
aim to reduce the production of NO did not affect viabil-
ity. Finally, we tried to increase the viability of
differentiating cells via the application of NAD+ to rescue
PARP activity. Again, QPRT-KO cells could not be rescued
from cell death during differentiation. In accordance with
these observations, QPRT-KO cells did not show changes
in the expression levels of any genes coding for PARP en-
zymes. In addition, QUIN could not be detected in any of
our samples, and none of the metabolites of tryptophan
catabolism was significantly changed upon KO of
QPRT in the performed metabolite assays. Taken to-
gether, we conclude that the detrimental effect of
QPRT loss on viability during SH-SY5Y differentiation
is independent of QUIN levels as well as of
QUIN-induced metabolic changes or the kynurenine
pathway in general.
To elucidate the underlying mechanisms of QPRT-
KO-induced cell death during SH-SY5Y neuronal differ-
entiation, we performed a hypothesis-free transcriptomic
approach. These findings suggest that loss of QPRT may
lead to an increased negative regulation of cytoskeleton
organization and to an inhibition of neuronal differenti-
ation and dendritic spine development. In our KD
model, we observed an alteration of neuritic complexity,
which strongly supports the functional role of QPRT in
these processes.
The functional association of QPRT with ASD is sup-
ported by the following results of our study: QPRT-KO
led to inhibition of GABRB3, which has been well estab-
lished as an ASD risk gene [62]. GABRB3 codes for a
subunit of an inhibitory GABA receptor. It is located on
Chr15q11-13, a region strongly implicated in ASD [63].
Similarly, the gene SNTG2 also downregulated in
QPRT-KO cells, codes for a synaptic scaffolding protein
involved in actin and PDZ domain binding. SNTG2 is lo-
cated in 2p25.3, a region linked to intellectual disability
[64] and associated with ASD [65]. Furthermore, SNTG2
protein interacts with neuroligins (NLGN), and this
interaction is altered by ASD associated mutations in
the NLGN genes [66]. QPRT was also found to physic-
ally interact with NLGN3 (neuroligin 3; [33]). Although
the function of this interaction is still unclear, it is likely
that QPRT is involved in the formation of the postsyn-
aptic density of GABAergic neurons. KCNQ3, another
ASD candidate gene, downregulated upon QPRT-KO,
encodes a protein regulating neuronal excitability.
Variants of this gene were found to be implicated in the
development of ASD and epilepsies [67]. Finally, we also
found CNTNAP2, a well-replicated risk gene for ASD
[68] located in 7q22-q36, to be downregulated in
QPRT-KO cells. In a previous study, we reported
CNTNAP2 promoter variants reducing transcription to
be risk factors for ASD [69].
Besides ASD-associated differentially regulated genes,
we report six novel candidates (i.e., COX17, GUCA1A,
COX17P1, VSTM2A, LINC01760, and ARHGAP20). At
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this stage, we cannot find any link to neuronal develop-
ment for the photoreceptor-associated guanylate cyclase
activator 1A GUCA1A, the preadipocyte development im-
plicated V-set and transmembrane domain containing 2A
VSTM2A gene, and the long intergenic non-coding RNA
LINC01760. However, the cytochrome c oxidase copper
chaperone COX17 (and its pseudogene COX17P1) and the
Rho GTPase-activating protein 20 ARHGAP20 are func-
tionally related to neuronal development: COX17 is part
of the terminal component of the mitochondrial respira-
tory chain, catalyzing the electron transfer from reduced
cytochrome c to oxygen, and might thus be involved in
the regulation of oxidative stress and energy metabolism,
both processes that have previously been associated with
ASD [36]. The ARHGAP20 enzyme is implicated in neur-
ite outgrowth and thus potentially associated with the here
observed neuromorphological phenotypes [70].
Translating the in vitro transcriptomic effect of
QPRT-KO in SH-SY5Y cells to the gene networks active
during human brain development [34], we observed differ-
entially regulated genes to be enriched in modules previ-
ously associated with cell cycle regulation (Kang-Module
1), transcription factors regulating progenitor cell fate
(Kang Module 20), neuronal development (Kang-Module
10 and 20), morphogenesis (Kang Modules 17 and 2), and
synaptic transmission (Kang-Module 2 and 15). In
addition, the Kang-Modules identified to be affected by
QPRT-KO were also reported to be highly co-expressed
(ρ ≥ 0.68) with markers for glutamatergic (Kang-Module
10) and GABAergic neurons (Kang-Modules 2 and 15) or
astrocytes (Kang-Module 2). In addition, Kang-Module 1
is implicated in the early development of the hippocampus
and amygdala, two regions significantly associated with
ASD after meta-analysis [71, 72]. These associations iden-
tified in the translational approach suggest that QPRT loss
might trigger alterations in the development of excitatory/
inhibitory neuronal networks, a pathomechanism postu-
lated to underlie the etiology of ASD [73, 74].
In summary, our findings allow us to conclude that in
the neuroblastoma model SH-SY5Y a loss of QPRT im-
pairs neuronal development in vitro by changing genetic
networks previously implicated in the etiology of ASD.
To confirm these results and the role of QPRT in the eti-
ology of ASD in general, further studies in other neur-
onal or animal models are needed. In particular,
analyzing the above described QPRT-KO mouse model
[30, 31] could elucidate the effect of QPRT loss at sys-
tems level.
Conclusions
Here, we report QPRT, a gene within the ASD-associated
16p11.2 CNV region, to be essential for and causally re-
lated to SH-SY5Y neuronal differentiation in vitro. This
corroborates postmortem findings of a disturbed
neuronal development in ASD. The functional mechan-
ism is still elusive; however, based on our results, we can
exclude alterations of QUIN levels or other products of
the kynurenine pathway in the here described SH-SY5Y
model. Further, the transcriptomic approach suggests
that a reduced availability of QPRT impacts on genes
and networks associated with ASD, such as neuron dif-
ferentiation, synapse organization, or the development of
excitatory/inhibitory neurons. Overall this study suggests
an alteration of QPRT expression or of QPRT related
genes to be underlying the etiology of ASD in 16p11.2
CNV carriers. Further studies are needed to confirm our
findings in more mature neuronal systems or animal
models.
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